ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
- University of New Mexico Cancer Center — Albuquerque, New Mexico
- Presbyterian Kaseman Hospital — Albuquerque, New Mexico
- Presbyterian Rust Medical Center/Jorgensen Cancer Center — Rio Rancho, New Mexico